

INCa and Cancéropôle Grand Ouest
translational research meeting

MAb IMPACT Final meeting

Towards The Clinical Use
Of Monoclonal Antibodies
With Higher Cytolytic
Efficacy In Cancer

Thursday 20 - Friday 21
November 2008

Tours, France

Sponsors

Under the auspices of and sponsored by



Sponsored by



What is MAb IMPACT?

MAb IMPACT project - IMProving ACTivation of FcγRIIIa expressing effector cells, pharmacogenetic-based optimisation of monoclonal antibody therapy for cancer - is a formative network funded by the french Institut National du Cancer since 2006.

This program involves 16 teams to determine how interactions between IgG and FcγRIIIa contribute to an anti-tumoral effect and how they could be optimised or exploited to improve recombinant monoclonal antibodies clinical efficacy.

Venue and general informations

Location

The congress will be held in the Charles de Gaulle conference room at the Conseil Général d'Indre et Loire, place de la préfecture in Tours, 10 min walk from the Tours station. For security reasons, an identity card will be required for access to the conference room.

Accommodation

Many hotels are located in the centre of Tours. A list is available at www.canceropole-grandouest.com

Access

By train there are many TGVs between the following stations: Charles de Gaulle airport, Paris Montparnasse, Massy-Palaiseau (connection with Orly airport), Lille, Bordeaux, Lyon, Strasbourg and Saint Pierre des Corps station. A 10 minutes shuttle then gives access to Tours station.

By car there are many motorways (A10 Paris Bordeaux, A28 from Normandy to Tours, A85 Nantes Vierzon then A71 Clermont-Ferrand). Prefer the Vinci car park in front of the Tours station.

Congress office

Lab. Immunologie
Faculté de Médecine
10 blvd Tonnellé
37 032 Tours cedex - FRANCE
Tél: +33(0)2 47 36 60 79
Fax: +33(0)2 34 38 94 12

Contacts

Scientific informations: Vanessa Suraud
vanessa.suraud@univ-tours.fr
Logistic informations: secimmun@med.univ-tours.fr

Evening seminar and dinner:

20 november 2008

Historical conference (in french):

*Les pionniers de la sérothérapie
anti-cancéreuse au 19^{ème} siècle*



Château & jardins
de
Villandry

www.chateauvillandry.com



Thursday 20 November 2008

Registration and lunch

13:00 - 13:30

Welcoming and introduction of the sessions

H Watier (University of Tours, France)

Session 1: Clinical background

Chairs: M Campone, E Gamelin

13:30 - 13:50

The impact of *FCGR3A* polymorphism on the response to therapeutic antibodies. An overview.

G Cartron (CHU Lapeyronnie, Montpellier, France)

13:50 - 14:10

***FCGR* polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu- positive metastatic breast cancer**

A Musolino (University Hospital of Parma, Italy)

14:10 - 14:30

Association of *FcγRIIa* and *FcγRIIIa* polymorphisms with clinical outcome in metastatic colorectal cancer patient treated with cetuximab and irinotecan

F Bibeau (CRLCC Val d'Aurelle, Montpellier, France)

14:30-14:50

Influence of *FCGR3A* polymorphism on the *in vivo* concentration-effect relationship of cytolytic antibodies

G Paintaud (University of Tours, France)

14:50-15:10

Afternoon coffee and discussion time

Session 2: Investigating *FcγRIIIa* expressing cells *in vivo*

Chairs: H Gascan, M Bonneville

15:10 - 15:30

A general picture of *FcγRIIIa* expression on lymphoid cells

B Clémenceau (INSERM U892, Nantes, France)

15:30 - 15:50

A general picture of *FcγRIIIa* expression on myeloid cells

Y Delneste (INSERM U564, Angers, France)

15:50-16:10

Exploring ADCC in patients under trastuzumab therapy: prediction of the clinical response ?

F Fagnoni (Salvatore Maugeri Foundation, Pavia, Italy)

16:10-16:30

An *in vitro* assay to functionally analyse *FcγRIIIa*

G Thibault (CHU of Tours, France)

16:30 -17:00

Discussion and conclusion on session 1 and 2

18:00

Departure to Château of Villandry

19:00

Les pionniers de la sérothérapie anti-cancéreuse au 19^{ème} siècle.

H Watier (University of Tours, France)

20:00

Dinner

Friday 21 November 2008

7:30 - 8:00

Welcoming coffee

Session 3: Clinical and pre-clinical developments : cytokines and glycoengineered antibodies

Chairs: Ph Solal-Céligny, G Thibault

8:00 - 8:20

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.

E Kimby (Karolinska University Hospital, Stockholm, Sweden)

8:20 – 8:40

Which cytokines of the IL-2 family would be the best candidate to synergise with monoclonal antibodies?

Y Jacques (INSERM U892, Nantes, France)

8:40 - 9:00

Intratumoral immunocytokine treatment results in enhanced antitumor

J Hank (University of Wisconsin, Madison, USA)

9:00-9:20

Role of cytokines on *FcγRIIIa* glycosylation and Ig binding to *FcγRIIIa*.

F Piller (CNRS UPR4301, Orléans, France)

9:20 - 9:40

NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependant cellular cytotoxicity against B-cell lymphoma

J Briones (Hematología Clínica, Hospital Santa Creu i Sant Pau, Barcelona, Spain)

9:40-10:00

Morning Coffee and discussion time

10:00-10:20

Synergistic effect of phosphostim targeting $\gamma\delta$ T cells and rituximab

JJ Fournié (INSERM U563, Toulouse, France)

10:20 - 10:40

Genetically modified antigen specific human-T lymphocytes and their potential use in cellular immunotherapy

H Vié (INSERM U892, Nantes, France)

10:40 - 11:00

A novel anti-CD20 monoclonal antibody with improved cytotoxicity against B-CLL cells

C de Romeuf (LFB, Lille, France)

11:00 - 11:20

Clinical development of a novel 3rd generation humanized Type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC

M Burgess (Roche Pharma, Welwyn, UK)

11:20 - 11:40

Final discussion, conclusion and end of meeting

Registration form

MAb IMPACT Final meeting

FILL IN AND RETURN WITH YOUR PAYMENT TO
THE CONGRESS OFFICE

*by checks to the order of: «Monsieur l'agent comptable
de l'université François-Rabelais-Tours»*

Last name:

First name:

Institute/Organisation:

Department:

Address:

City:

Postal code:

Country:

Phone:

Fax:

Email (required):

	Members of MAb IMPACT network	External of MAb IMPACT network	Students external of MAb IMPACT network
Registration price	FREE ENTRANCE*	20 €	FREE ENTRANCE*
Conference and dinner at Villandry	50 €	80 €	80 €

*includes admission to scientific sessions, coffee breaks,
thursday lunch. Does not include transport and hotel nor
thursday dinner.

**Answer required before
2008 NOVEMBER, 7th**